NVAX Novavax
- 4.710
- +0.040+0.86%
- 4.770
- +0.060+1.27%
Novavax News
Novavax (NVAX) Increases Despite Market Slip: Here's What You Need to Know
WHO Picks JN.1 Variant for Next Set of COVID Vaccines
Novavax Prepared to Deliver Protein-based Non-mRNA JN.1 COVID-19 Vaccine in Line With WHO Recommendation This Fall
Today the World Health Organization's (WHO) Technical Advisory Group on COVID-19 Vaccine Composition recommended the use of a monovalent JN.1 lineage COVID-19 vaccine as one approach to address the on
12 Most Shorted Stocks in 2024
Novavax To Supply Updated COVID-19 Vaccine To Private Healthcare Providers In The United Kingdom
Novavax To Supply Updated COVID-19 Vaccine To Private Healthcare Providers In The United Kingdom
Novavax to Supply Updated COVID-19 Vaccine to Private Healthcare Providers in the United Kingdom
For Global Investor Audience OnlyNovavax's Nuvaxovid XBB.1.5 dispersion for injection, COVID-19 Vaccine (recombinant, adjuvanted) (NVX-CoV2601) is now available to pharmacies across the United Kingdom
Sector Update: Health Care Stocks Gain Monday Afternoon
Health care stocks advanced Monday afternoon with the NYSE Health Care Index rising 0.3% and the Health Care Select Sector SPDR Fund (XLV) up 0.2%. The iShares Biotechnology ETF (IBB) fell 1%. In corp
Novavax Shareholder Shah Capital Pushes to Add 2 Nominees to Company's Board
Novavax (NVAX) was narrowly higher in morning trading on Monday after Shah Capital called for the biotechnology company to add two of its director nominees to its board. The North Carolina hedge fund
Goldman Sachs surpassed expectations by 4.2% in Q1 revenue. Salesforce fell 3.1%, Informatica fell 2.4%, and the merger and acquisition deal between the two sides is nearing completion. Novavax rose 3.5%, and the majority shareholders called for an “urgen
Goldman Sachs surpassed expectations by 4.2% in Q1 revenue. Salesforce fell 3.1%, Informatica fell 2.4%, and the merger and acquisition deal between the two sides is nearing completion. Novavax rose 3.5%, and the majority shareholders called for an “urgent restructuring” of the board of directors.
What's Going On With Novavax Stock Today?
Novavax Inc (NASDAQ:NVAX) shares are trading higher Monday after Shah Capital Management reported a 6.66% stake in the company and nominated two directors for the company's board.What Happened: In a n
Novavax was recommended by hedge fund investors, and two new director candidates rose about 3.5% in the premarket
Greenway, April 15 | US hedge fund Shah Capital recommended that Covid-19 vaccine producer Novavax appoint two new independent directors Suresh Katta and Venkat Peri to join the board of directors. Shah Capital holds approximately 6.7% of Novavax's common stock in circulation. It said the low share price reflects the board and management's failure to take full advantage of many important competitive advantages and seize the opportunities of the entire market. Novavax said in a statement that we welcome shareholders' views and value them about me
Novavax Shares Are Trading Higher After Shah Capital Management Reported a 6.66% Stake in the Company.
Novavax Shares Are Trading Higher After Shah Capital Management Reported a 6.66% Stake in the Company.
Shah Capital Calls for Board Shake-up at Novavax
Shah Capital Management Reported 6.66% Stake in Novavax In 13D Filing
Shah Capital Management Reported 6.66% Stake in Novavax In 13D Filing
Novavax Failed to Capitalize on Fears Surrounding MRNA Vaccines, Activist Investor Says
By Louis Goss Hedge fund Shah Capital on Monday called for an "urgent shake up" at the board of Novavax over claims its management has failed to capitalize on safety concerns surrounding mRNA vaccine
Express News | Major shareholders of US pharmaceutical company Novavax urge it to adjust its board of directors and reform its sales strategy
Shah Capital Nominates Two Independent Director Candidates For Novavax
Shah Capital, which owns approximately 6.7% of the outstanding common stock of Novavax, recommends the appointment to Novavax board of two new independent directors: Suresh Katta and Venkat Peri. Shah
Novavax (NASDAQ:NVAX) Jumps Amid Activist Investor Push
UPDATE 1-Hedge Fund Shah Capital Urges Novavax Board Shake-up, FT Says
Better Buy: Bluebird Bio Vs. Novavax
Analysis
Price Target
No Data
